1. Home
  2. PBHC vs KPTI Comparison

PBHC vs KPTI Comparison

Compare PBHC & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBHC
  • KPTI
  • Stock Information
  • Founded
  • PBHC 1859
  • KPTI 2008
  • Country
  • PBHC United States
  • KPTI United States
  • Employees
  • PBHC N/A
  • KPTI N/A
  • Industry
  • PBHC Major Banks
  • KPTI Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBHC Finance
  • KPTI Health Care
  • Exchange
  • PBHC Nasdaq
  • KPTI Nasdaq
  • Market Cap
  • PBHC 92.9M
  • KPTI 102.4M
  • IPO Year
  • PBHC N/A
  • KPTI 2013
  • Fundamental
  • Price
  • PBHC $15.14
  • KPTI $6.08
  • Analyst Decision
  • PBHC
  • KPTI Strong Buy
  • Analyst Count
  • PBHC 0
  • KPTI 7
  • Target Price
  • PBHC N/A
  • KPTI $31.71
  • AVG Volume (30 Days)
  • PBHC 6.2K
  • KPTI 313.4K
  • Earning Date
  • PBHC 10-31-2025
  • KPTI 11-03-2025
  • Dividend Yield
  • PBHC 2.64%
  • KPTI N/A
  • EPS Growth
  • PBHC N/A
  • KPTI N/A
  • EPS
  • PBHC 0.28
  • KPTI N/A
  • Revenue
  • PBHC $39,015,000.00
  • KPTI $137,269,000.00
  • Revenue This Year
  • PBHC N/A
  • KPTI $4.87
  • Revenue Next Year
  • PBHC N/A
  • KPTI $9.20
  • P/E Ratio
  • PBHC $53.94
  • KPTI N/A
  • Revenue Growth
  • PBHC N/A
  • KPTI N/A
  • 52 Week Low
  • PBHC $13.55
  • KPTI $3.51
  • 52 Week High
  • PBHC $18.53
  • KPTI $16.95
  • Technical
  • Relative Strength Index (RSI)
  • PBHC 50.29
  • KPTI 48.39
  • Support Level
  • PBHC $14.65
  • KPTI $6.09
  • Resistance Level
  • PBHC $15.20
  • KPTI $6.60
  • Average True Range (ATR)
  • PBHC 0.18
  • KPTI 0.45
  • MACD
  • PBHC -0.04
  • KPTI 0.02
  • Stochastic Oscillator
  • PBHC 82.44
  • KPTI 46.40

About PBHC Pathfinder Bancorp Inc. (MD)

Pathfinder Bancorp Inc is a holding company for Pathfinder Bank. The Pathfinder Bank is a commercial bank engaged in attracting deposits from the general public and investing such deposits, together with other sources of funds, in loans secured by residential real estate, commercial real estate, small business loans, and consumer loans. The bank invests a portion of its assets in debt securities issued by the United States Government and its agencies and sponsored enterprises, state and municipal obligations, corporate debt securities, mutual funds, and equity securities. The principal source of income is interest on loans and investment securities.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: